Feb 15, 2023 / 06:00PM GMT
David Reed Risinger - SVB Securities LLC, Research Division - Senior MD
Great. Good afternoon, everyone, and thank you for joining us for this next session with JNJ. My name is Dave Risinger, and I cover diversified biopharmaceuticals. It's very much my pleasure to welcome 2 senior leaders at Johnson & Johnson. So that is Biljana Naumovic. She is Worldwide President of Global Oncology; and also Peter Lebowitz, who's Global Therapeutic Head of Oncology R&D.
Questions and Answers:
David Reed Risinger - SVB Securities LLC, Research Division - Senior MDSo I thought we'd start off with a high-level question for Biljana. Could you discuss -- well, first of all, congrats on all of the phenomenal progress and momentum for your organization and what you're leading. I thought we'd start off with asking you to discuss your vision for capitalizing on the tremendous success that you've already had and driving further success in multiple myeloma.
Biljana Naumovic -
Thank you, David. And it's really a pleasure to be with you
Trustpilot
